Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

le.  NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.  

In addition to the fully-enrolled Phase 2 studies in platinum-refractory/resistant ovarian cancer and metastatic breast cancer, NKTR-102 is also being tested in a separate Phase 2 clinical trial in patients with second-line colorectal cancer and a Phase 1 clinical trial evaluating NKTR-102 in combination with 5-FU therapy.  An expansion arm of the Phase 2 study of single-agent NKTR-102 in platinum-refractory/resistant ovarian cancer in women who failed prior Doxil therapy is also currently enrolling.  A Phase 3 study of single-agent NKTR-102 is planned in metastatic breast cancer.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 pr
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
... , , HOUSTON, Nov. 16 Cyberonics, Inc. ... to its tax position. , In its fiscal second quarter ... GAAP tax benefit of approximately $40 million resulting from the ... losses. The recognition of this tax benefit follows from ...
... , , LOS ANGELES, Nov. ... a 40-year-old Indian rhinoceros, has successfully completed treatment for ... to deliver electronic, x-ray based therapy directly to cancer ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091116/SF11909 ) , Randa was ...
Cached Medicine Technology:Cyberonics Provides Update on Tax Position 2Cyberonics Provides Update on Tax Position 3Cyberonics Provides Update on Tax Position 4L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 2L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 3
(Date:9/3/2015)... York, New York (PRWEB) , ... September 03, 2015 , ... ... of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical ... College. , Dr. Winchell is a nationally renowned expert in care for the critically ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, to their ... board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... a top review from Clinicians Report of Provo, Utah. The Clinicians Report is ... a selected group of dentists located throughout the U.S. Whiter Image's In-Office whitening ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2
... relative of the highly pathogenic avian influenza virus (H5N1) ... including// chlorination, ultraviolet (UV) radiation and bacterial digesters. The ... case of the pathways by which the influenza could ... related virus, called H5N2, to see whether a hypothetical ...
... Although it’s our most vital organ, surprisingly little ... That makes it harder to uncover what’s gone ... other brain-associated disorders, and ultimately, it often leaves ... such as Alzheimer’s and Parkinson’s disease, schizophrenia, attention ...
... management of the health service has been revealed by the ... nurses, measly pay rises// and strikes. ,A copy ... reveals that 37000 posts are in danger as the Government ... 2.7 per cent cut in the workforce. ,NHS ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... international homeopathy conference is taking place in this Taj ... and eight countries.// ,The four-day meet, which ... AIDS and "other difficult subjects which have proved a ... secretary, told IANS., ,The slogan of the conference ...
... surgical team was led by Dr. Christopher Moir at Minnesota's ... North Dakota// (ND) and now they are on the challenging ... Madysen Fitterer, the twin girls born on Aug. 8 to ... the chest - were both doing very well following the ...
Cached Medicine News:Health News:Avian Flu Unlikely to Spread Through Water Systems 2Health News:Researchers Looking for Genes That Control the Brain 2Health News:A Secret Dossier Predicts Major Changes At NHS, England 2
... A new Transnasal Lacrimal Stent has been ... B. Becker, M.D., the Transnasal Lacrimal Stent addressed ... and other forms of endoscopic DCR. Brought in ... relatively large diameter. Because there is no need ...
...
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... SIREMOBIL Iso-C3D is based on SIREMOBIL ... the industry. In the intra-operative 3D-Mode, the ... the motorized 190 orbital movement. This allows ... in greater precision during the procedure. This ...
Medicine Products: